For high-risk patients, oral acitretin has the strongest evidence for preventing skin cancers, with 30-50% efficacy. This is significantly higher than the debatable 20% efficacy of nicotinamide (Vitamin B3). Topical treatments like retinoids are considered ineffective for this purpose.
The introduction of immunotherapy, starting with ipilimumab in 2011, revolutionized advanced melanoma treatment. Before this, a diagnosis was often a death sentence. The impact is quantifiable, with annual deaths dropping from nearly 14,000 to around 8,000, showcasing a dramatic shift in prognosis.
Among solid organ transplant patients, who are already at high risk for skin cancer, heart transplant recipients are at the greatest risk. This is specifically due to the type and duration of immunosuppressive drugs required to prevent organ rejection, highlighting a critical sub-population for dermatologic surveillance.
The appearance of basal cell carcinoma in a patient under 30 is a powerful diagnostic indicator for Gorlin syndrome. This genetic condition cannot be explained by sun exposure alone and is associated with other findings like palmar pits, warranting immediate investigation into family history and genetic testing.
Unlike photon radiation ("flashlights") used for deep tumors, electron radiation ("tennis balls") has mass and stops near the surface. This makes it an ideal tool for treating many skin cancers, as it minimizes radiation dose and toxicity to underlying healthy tissues and organs.
For skin cancer patients with comorbidities like peripheral vascular disease or poorly controlled diabetes, a "low and slow" radiation course over six weeks is preferred. This minimizes the risk of creating a chronic, non-healing wound, which can be a more significant long-term problem than the cancer itself.